Minerva Neurosciences Inc (NERV) USD0.0001

Sell:$1.46Buy:$1.75$0.15 (8.83%)

Prices delayed by at least 15 minutes
Sell:$1.46
Buy:$1.75
Change:$0.15 (8.83%)
Prices delayed by at least 15 minutes
Sell:$1.46
Buy:$1.75
Change:$0.15 (8.83%)
Prices delayed by at least 15 minutes

Company Information

About this company

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

Key people

Remy Luthringer
Executive Chairman of the Board of Directors, Chief Executive Officer
Geoffrey Race
President
Frederick Ahlholm
Chief Financial Officer, Senior Vice President, Secretary
Joseph Reilly
Chief Operating Officer, Senior Vice President
Michael Davidson
Chief Medical Officer
Hans Peter Hasler
Independent Director
David J. Kupfer
Independent Director
Fouzia Laghrissi-Thode
Independent Director
Jan G. Van Heek
Independent Director
Click to see more

Key facts

  • EPIC
    NERV
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US6033802058
  • Market cap
    $12.66m
  • Employees
    8
  • Shares in issue
    6.99m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.